ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2550 |
|
953769-46-5 |
Sotuletinib (BLZ945) 98+% |
C20H22N4O3S | |
CL2536 |
|
1020172-07-9 |
Rebastinib (DCC-2036) 98+% |
C30H28FN7O3 | |
CL2519 |
|
950769-58-1 |
Quizartinib (AC220) 98+% |
C29H32N6O4S | |
CL2508 |
|
1360460-82-7 |
Anlotinib Dihydrochloride (AL3818 Dihydrochloride); Anlotinib 2HCl 98+% |
C23H24Cl2FN3O3 | |
CL2492A |
|
1421783-64-3 |
Olverembatinib dimesylate (GZD824 dimesylate; HQP1351 dimesylate) 98+% |
C31H35F3N6O7S2 | |
CL2492 |
|
1257628-77-5 |
Olverembatinib (GZD824; HQP1351) 98+% |
C29H27F3N6O | |
CL2375A |
|
923288-90-8 |
Nilotinib Hydrochloride Monohydrate;Nilotinib HCl Monohydrate 98+% |
C28H25ClF3N7O2 | |
CLA1359 |
|
1365287-97-3 |
Emibetuzumab (Anti-HGFR / c-Met) 95+% |
— | |
CLA1336 |
|
1243266-04-7 |
Tovetumab (Anti-PDGFRA / CD140a) 95+% |
— | |
CLA1318 |
|
1204390-13-5 |
Dusigitumab 95+% |
— | |
CLA1314 |
|
1310460-86-6 |
Modotuximab (Anti-ERBB1 / EGFR / HER1) 95+% |
— | |
CLA1310 |
|
1312797-14-0 |
Parsatuzumab (Anti-EGFL7) 95+% |
— | |
CLA1304 |
|
959963-46-3 |
Imgatuzumab (Anti-ERBB1 / EGFR / HER1) 95+% |
— | |
CLA1303 |
|
1310460-85-5 |
Futuximab 95+% |
— | |
CLA1300 |
|
1314238-96-4 |
Duligotuzumab 95+% |
— | |
CLA1295 |
|
1262787-83-6 |
Patritumab (Anti-ERBB3 / HER3) 95+% |
— | |
CLA1280 |
|
1174900-84-5 |
Ficlatuzumab (Anti-HGF / SF) 95+% |
— | |
CLA1270 |
|
1133766-06-9 |
Onartuzumab (Anti-HGFR / c-Met) 95+% |
— | |
CLA1269 |
|
1206681-39-1 |
Namilumab (Anti-CSF2 / GM-CSF) 95+% |
— | |
CLA1256 |
|
1024603-93-7 |
Olaratumab (Anti-PDGFRA / CD140a) 95+% |
— | |